Stay updated on Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page.

Latest updates to the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe new screenshot shows only minor formatting and layout adjustments with no changes to core study details (title, conditions, eligibility criteria, locations, or results). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check32 days agoChange DetectedAdded an important government-operating-status notice and a new version tag v3.2.0; removed the old version tag v3.1.0.SummaryDifference2%

- Check39 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

- Check53 days agoChange DetectedThe page updates from v3.0.1 to v3.0.2, with the Back to Top element removed; no substantive changes to core content or pricing are indicated.SummaryDifference0.1%

- Check60 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.SummaryDifference0.1%

- Check68 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as the introduction of new medical terms and drug names related to ovarian cancer treatment. Notably, the revision number has been updated to v3.0.0.SummaryDifference6%

Stay in the know with updates to Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page.